We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Abbott Diagnostics- Hematology Division

Download Mobile App




Events

ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.

Blood Test Distinguishes Epileptic Seizures From PNES

By LabMedica International staff writers
Posted on 16 Feb 2021
Print article
Image: An association of epileptic and non-epileptic seizures and changes in circulating plasma proteins is linked to neuroinflammation (Photo courtesy of Evogen, Inc).
Image: An association of epileptic and non-epileptic seizures and changes in circulating plasma proteins is linked to neuroinflammation (Photo courtesy of Evogen, Inc).
Epilepsy is a central nervous system (neurological) disorder in which brain activity becomes abnormal, causing seizures or periods of unusual behavior, sensations, and sometimes loss of awareness. Epilepsy affects both males and females of all races, ethnic backgrounds and ages.

Epilepsy affects over 70 million people worldwide. This common brain condition has multiple risk factors and a strong genetic predisposition. Psychogenic non-epileptic seizures (PNES) are events resembling an epileptic seizure, but without the characteristic electrical discharges associated with epilepsy. They are of psychological origin, and are one type of non-epileptic seizure mimicked.

Neuroscientists from the University of Maryland (Baltimore, MD, USA) and their colleagues collected daily blood samples from patients evaluated in the epilepsy monitoring unit (EMU) within 24 hours after electroencephalograms (EEG) confirmed epileptic seizures (ES) or PNES and plasma was isolated. A total of 137 patients were evaluated in the EMU for differential diagnosis or pre-surgical evaluation; 29 healthy volunteers also were prospectively enrolled in the study in 2014-2015. Of the 137 initially enrolled patients, 48 were excluded because no definitive diagnosis could be made. Timing of blood draws excluded another 42 patients, leaving 23 epilepsy patients (65.2% women, mean age 44) and 24 PNES patients (79.2% women, mean age 44). Multiple races and ethnicities were represented.

The scientists quantified the levels of 51 candidate plasma proteins using an automated, multiplexed, sandwich enzyme-linked immunosorbent assay (EvoScoreDx, Cognizance Biomarkers, Spring House, PA, USA) and then integrated and analyzed using a diagnostic algorithm. All epileptic seizure patients had confirmed seizure on EEG; average seizure duration was 2.6 minutes. Of note, 79% of PNES patients and all epileptic seizure patients had motor manifestations in their seizures, and 83% of epileptic seizure patients had drug-resistant epilepsy.

The team reported that a combination of protein concentrations, TNF-related apoptosis-inducing ligand (TRAIL), Intercellular Adhesion Molecule 1 (ICAM-1), monocyte chemoattractant protein 2 (MCP-2) and Tumor necrosis factor receptor 1 (TNF-R1) provided a probability that a patient recently experienced a seizure with TRAIL and ICAM-1 higher in PNES than ES, and MCP-2 and TNF-R1 higher in ES than PNES. The diagnostic algorithm yielded an AUC of 0.94 ± 0.07, sensitivity of 82.6% and specificity of 91.6%. Further, expanding the diagnostic algorithm to include previously identified PNES risk factors enhanced diagnostic performance with AUC of 0.97 ±0 .05, sensitivity of 91.3%, and specificity of 95.8%.

Peter Crino, MD, PhD, a Professor of Neuroscience and a senior author of the study and his colleagues noted that epileptic seizures can activate both systemic and brain proinflammatory pathways including enhanced interleukin 1β production, activation of toll-like receptor 4, mammalian target of rapamycin, and mitogen-activated protein kinase cascades, attraction of activated lymphocytes, activation of microglia and macrophages, and alteration of astrocyte physiology.

The authors concluded that the four plasma proteins, TRAIL, ICAM-1, MCP-2 and TNF-R1, could provide a rapid, cost-effective, and accurate blood-based diagnostic test to confirm recent ES or PNES. The study was published on January 25, 2021 in the journal Neurology.

Related Links:
University of Maryland
Cognizance Biomarkers


Gold Supplier
Blood Glucose Laboratory Analyzer
Nova Primary
New
D-Dimer ELISA Kit
D-Dimer AccuBind ELISA Kit
New
Next-Generation Sequencing (NGS) Workstation
NGS STAR for COVID-19
New
Refrigerated Centrifuge
Centrisart G-26C

Print article
BIOHIT  Healthcare OY

Channels

Industry

view channel
Image: Quidel Receives Amended FDA Emergency Use Authorization for New AI-Powered Sofia Q Rapid Antigen Test Device (Photo courtesy of Quidel Corporation)

Quidel Receives Amended FDA Emergency Use Authorization for New AI-Powered Sofia Q Rapid Antigen Test Device

Quidel Corporation (San Diego, CA, USA) has received an amended Emergency Use Authorization (EUA) from the US Food and Drug Administration (FDA) allowing the company to market Sofia Q, its latest addition... Read more
Copyright © 2000-2021 Globetech Media. All rights reserved.